nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Etoposide—brain cancer	0.389	0.458	CbGbCtD
Metyrapone—CYP3A4—Temozolomide—brain cancer	0.168	0.198	CbGbCtD
Metyrapone—CYP3A4—Lomustine—brain cancer	0.143	0.168	CbGbCtD
Metyrapone—CYP2E1—Etoposide—brain cancer	0.114	0.134	CbGbCtD
Metyrapone—CYP3A4—Etoposide—brain cancer	0.0346	0.0407	CbGbCtD
Metyrapone—Bone marrow depression—Hydroxyurea—brain cancer	0.00474	0.0594	CcSEcCtD
Metyrapone—CYP2A6—CYP2E1 reactions—CYP2C9—brain cancer	0.00472	0.0664	CbGpPWpGaD
Metyrapone—Pancytopenia—Lomustine—brain cancer	0.00388	0.0486	CcSEcCtD
Metyrapone—CYP2E1—CYP2E1 reactions—CYP2C9—brain cancer	0.00373	0.0525	CbGpPWpGaD
Metyrapone—ABCC3—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00321	0.0451	CbGpPWpGaD
Metyrapone—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00313	0.044	CbGpPWpGaD
Metyrapone—CYP11B2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00309	0.0434	CbGpPWpGaD
Metyrapone—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00306	0.043	CbGpPWpGaD
Metyrapone—Endocrine disorder—Temozolomide—brain cancer	0.00301	0.0378	CcSEcCtD
Metyrapone—CYP2A6—Xenobiotics—CYP2C9—brain cancer	0.00293	0.0412	CbGpPWpGaD
Metyrapone—Alopecia—Lomustine—brain cancer	0.00289	0.0362	CcSEcCtD
Metyrapone—CYP2A6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00282	0.0396	CbGpPWpGaD
Metyrapone—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.0027	0.0379	CbGpPWpGaD
Metyrapone—CYP11B1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00266	0.0374	CbGpPWpGaD
Metyrapone—CYP11B2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00254	0.0357	CbGpPWpGaD
Metyrapone—Pancytopenia—Procarbazine—brain cancer	0.00246	0.0309	CcSEcCtD
Metyrapone—CYP2E1—Xenobiotics—CYP2C9—brain cancer	0.00231	0.0325	CbGpPWpGaD
Metyrapone—Pain—Carboplatin—brain cancer	0.00227	0.0285	CcSEcCtD
Metyrapone—CYP2E1—Tamoxifen metabolism—CYP2C9—brain cancer	0.00223	0.0313	CbGpPWpGaD
Metyrapone—CYP11B1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00219	0.0307	CbGpPWpGaD
Metyrapone—CYP2A6—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00201	0.0283	CbGpPWpGaD
Metyrapone—Pancytopenia—Hydroxyurea—brain cancer	0.00191	0.0239	CcSEcCtD
Metyrapone—Alopecia—Procarbazine—brain cancer	0.00183	0.023	CcSEcCtD
Metyrapone—Hypertension—Procarbazine—brain cancer	0.00156	0.0196	CcSEcCtD
Metyrapone—Pancytopenia—Carmustine—brain cancer	0.00154	0.0193	CcSEcCtD
Metyrapone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00151	0.0213	CbGpPWpGaD
Metyrapone—Pancytopenia—Temozolomide—brain cancer	0.00149	0.0187	CcSEcCtD
Metyrapone—Vomiting—Lomustine—brain cancer	0.00148	0.0185	CcSEcCtD
Metyrapone—Angiopathy—Hydroxyurea—brain cancer	0.00146	0.0183	CcSEcCtD
Metyrapone—Alopecia—Hydroxyurea—brain cancer	0.00142	0.0178	CcSEcCtD
Metyrapone—Nausea—Lomustine—brain cancer	0.00138	0.0173	CcSEcCtD
Metyrapone—Hypotension—Procarbazine—brain cancer	0.00138	0.0173	CcSEcCtD
Metyrapone—CYP11B2—Biological oxidations—CYP2C9—brain cancer	0.00135	0.0189	CbGpPWpGaD
Metyrapone—CYP11B2—Metapathway biotransformation—CYP2C9—brain cancer	0.00133	0.0187	CbGpPWpGaD
Metyrapone—Pain—Procarbazine—brain cancer	0.00126	0.0158	CcSEcCtD
Metyrapone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00122	0.0171	CbGpPWpGaD
Metyrapone—Gastrointestinal pain—Procarbazine—brain cancer	0.00121	0.0151	CcSEcCtD
Metyrapone—CYP2A6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.0012	0.0169	CbGpPWpGaD
Metyrapone—Pancytopenia—Etoposide—brain cancer	0.00119	0.0149	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00118	0.0148	CcSEcCtD
Metyrapone—Abdominal pain—Procarbazine—brain cancer	0.00117	0.0146	CcSEcCtD
Metyrapone—CYP11B1—Biological oxidations—CYP2C9—brain cancer	0.00116	0.0163	CbGpPWpGaD
Metyrapone—Alopecia—Carmustine—brain cancer	0.00115	0.0144	CcSEcCtD
Metyrapone—CYP11B1—Metapathway biotransformation—CYP2C9—brain cancer	0.00115	0.0161	CbGpPWpGaD
Metyrapone—Angiopathy—Temozolomide—brain cancer	0.00114	0.0143	CcSEcCtD
Metyrapone—Nervous system disorder—Hydroxyurea—brain cancer	0.00112	0.014	CcSEcCtD
Metyrapone—Alopecia—Temozolomide—brain cancer	0.00111	0.0139	CcSEcCtD
Metyrapone—Skin disorder—Hydroxyurea—brain cancer	0.00111	0.0139	CcSEcCtD
Metyrapone—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.00107	0.0151	CbGpPWpGaD
Metyrapone—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.00103	0.0145	CbGpPWpGaD
Metyrapone—CYP2A6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000986	0.0139	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000985	0.0124	CcSEcCtD
Metyrapone—Hypertension—Carmustine—brain cancer	0.000976	0.0122	CcSEcCtD
Metyrapone—Pain—Hydroxyurea—brain cancer	0.000976	0.0122	CcSEcCtD
Metyrapone—Dizziness—Procarbazine—brain cancer	0.000975	0.0122	CcSEcCtD
Metyrapone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000961	0.0135	CbGpPWpGaD
Metyrapone—CYP2E1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000948	0.0133	CbGpPWpGaD
Metyrapone—Hypertension—Temozolomide—brain cancer	0.000943	0.0118	CcSEcCtD
Metyrapone—Vomiting—Procarbazine—brain cancer	0.000937	0.0118	CcSEcCtD
Metyrapone—Headache—Procarbazine—brain cancer	0.000923	0.0116	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000923	0.0116	CcSEcCtD
Metyrapone—Angiopathy—Etoposide—brain cancer	0.000911	0.0114	CcSEcCtD
Metyrapone—Alopecia—Etoposide—brain cancer	0.000887	0.0111	CcSEcCtD
Metyrapone—Nausea—Procarbazine—brain cancer	0.000876	0.011	CcSEcCtD
Metyrapone—Nervous system disorder—Temozolomide—brain cancer	0.000874	0.011	CcSEcCtD
Metyrapone—Skin disorder—Temozolomide—brain cancer	0.000866	0.0109	CcSEcCtD
Metyrapone—Hypotension—Carmustine—brain cancer	0.000862	0.0108	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Carmustine—brain cancer	0.000796	0.00999	CcSEcCtD
Metyrapone—Pain—Carmustine—brain cancer	0.000789	0.00989	CcSEcCtD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000779	0.011	CbGpPWpGaD
Metyrapone—Gastrointestinal disorder—Temozolomide—brain cancer	0.000769	0.00965	CcSEcCtD
Metyrapone—Pain—Temozolomide—brain cancer	0.000762	0.00956	CcSEcCtD
Metyrapone—Hypertension—Etoposide—brain cancer	0.000754	0.00947	CcSEcCtD
Metyrapone—Dizziness—Hydroxyurea—brain cancer	0.000754	0.00947	CcSEcCtD
Metyrapone—Gastrointestinal pain—Carmustine—brain cancer	0.000754	0.00946	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000739	0.00927	CcSEcCtD
Metyrapone—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000737	0.0104	CbGpPWpGaD
Metyrapone—Abdominal pain—Carmustine—brain cancer	0.000729	0.00915	CcSEcCtD
Metyrapone—Gastrointestinal pain—Temozolomide—brain cancer	0.000729	0.00914	CcSEcCtD
Metyrapone—Vomiting—Hydroxyurea—brain cancer	0.000725	0.0091	CcSEcCtD
Metyrapone—Headache—Hydroxyurea—brain cancer	0.000715	0.00897	CcSEcCtD
Metyrapone—Abdominal pain—Temozolomide—brain cancer	0.000705	0.00884	CcSEcCtD
Metyrapone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000702	0.00988	CbGpPWpGaD
Metyrapone—Skin disorder—Etoposide—brain cancer	0.000693	0.00869	CcSEcCtD
Metyrapone—Nausea—Hydroxyurea—brain cancer	0.000678	0.0085	CcSEcCtD
Metyrapone—Hypotension—Etoposide—brain cancer	0.000666	0.00836	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Etoposide—brain cancer	0.000616	0.00772	CcSEcCtD
Metyrapone—Dizziness—Carmustine—brain cancer	0.00061	0.00765	CcSEcCtD
Metyrapone—Pain—Etoposide—brain cancer	0.00061	0.00765	CcSEcCtD
Metyrapone—Dizziness—Temozolomide—brain cancer	0.000589	0.00739	CcSEcCtD
Metyrapone—Vomiting—Carmustine—brain cancer	0.000586	0.00736	CcSEcCtD
Metyrapone—Gastrointestinal pain—Etoposide—brain cancer	0.000583	0.00732	CcSEcCtD
Metyrapone—Headache—Carmustine—brain cancer	0.000578	0.00725	CcSEcCtD
Metyrapone—Vomiting—Temozolomide—brain cancer	0.000567	0.00711	CcSEcCtD
Metyrapone—Abdominal pain—Etoposide—brain cancer	0.000564	0.00707	CcSEcCtD
Metyrapone—Headache—Temozolomide—brain cancer	0.000558	0.00701	CcSEcCtD
Metyrapone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000555	0.00781	CbGpPWpGaD
Metyrapone—Nausea—Carmustine—brain cancer	0.000548	0.00687	CcSEcCtD
Metyrapone—Nausea—Temozolomide—brain cancer	0.000529	0.00664	CcSEcCtD
Metyrapone—CYP2A6—Biological oxidations—CYP2C9—brain cancer	0.000524	0.00736	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000517	0.00727	CbGpPWpGaD
Metyrapone—Dizziness—Etoposide—brain cancer	0.000472	0.00592	CcSEcCtD
Metyrapone—Vomiting—Etoposide—brain cancer	0.000453	0.00569	CcSEcCtD
Metyrapone—Headache—Etoposide—brain cancer	0.000447	0.00561	CcSEcCtD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000446	0.00627	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000446	0.00627	CbGpPWpGaD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00044	0.00619	CbGpPWpGaD
Metyrapone—Nausea—Etoposide—brain cancer	0.000424	0.00531	CcSEcCtD
Metyrapone—CYP2E1—Biological oxidations—CYP2C9—brain cancer	0.000414	0.00582	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP2C9—brain cancer	0.000408	0.00574	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—RELA—brain cancer	0.000397	0.00558	CbGpPWpGaD
Metyrapone—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000379	0.00533	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000378	0.00532	CbGpPWpGaD
Metyrapone—ABCC3—Fluoropyrimidine Activity—TP53—brain cancer	0.000375	0.00528	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—S100A10—brain cancer	0.000368	0.00518	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000361	0.00508	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—IL2—brain cancer	0.000357	0.00502	CbGpPWpGaD
Metyrapone—CYP11B1—Corticotropin-releasing hormone—CTNNB1—brain cancer	0.000345	0.00485	CbGpPWpGaD
Metyrapone—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000336	0.00472	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000326	0.00458	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000321	0.00451	CbGpPWpGaD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TP53—brain cancer	0.000235	0.00331	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000235	0.0033	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CYP2C9—brain cancer	0.00023	0.00324	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CYP2C9—brain cancer	0.000199	0.00279	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—BSG—brain cancer	0.000196	0.00275	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.000192	0.0027	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000189	0.00266	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—TRPC6—brain cancer	0.00017	0.00239	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—BSG—brain cancer	0.000169	0.00237	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—IDH1—brain cancer	0.000168	0.00237	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—IDH1—brain cancer	0.000145	0.00204	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP2C9—brain cancer	0.000143	0.00201	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	0.000137	0.00193	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ENO2—brain cancer	0.000133	0.00187	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—BSG—brain cancer	0.000122	0.00171	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	0.000118	0.00166	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ENO2—brain cancer	0.000115	0.00161	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—IDH1—brain cancer	0.000105	0.00147	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP2C9—brain cancer	8.96e-05	0.00126	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.51e-05	0.0012	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ENO2—brain cancer	8.26e-05	0.00116	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—BSG—brain cancer	7.62e-05	0.00107	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2C9—brain cancer	7.08e-05	0.000995	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—IDH1—brain cancer	6.55e-05	0.000921	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CG—brain cancer	6.11e-05	0.000859	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—BSG—brain cancer	6.02e-05	0.000846	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CG—brain cancer	5.26e-05	0.00074	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ENO2—brain cancer	5.18e-05	0.000728	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—IDH1—brain cancer	5.17e-05	0.000728	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ENO2—brain cancer	4.09e-05	0.000575	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CG—brain cancer	3.79e-05	0.000533	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2C9—brain cancer	3.28e-05	0.000462	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—BSG—brain cancer	2.79e-05	0.000393	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—IDH1—brain cancer	2.4e-05	0.000338	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CG—brain cancer	2.37e-05	0.000334	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ENO2—brain cancer	1.9e-05	0.000267	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CG—brain cancer	1.88e-05	0.000264	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CG—brain cancer	8.71e-06	0.000122	CbGpPWpGaD
